IT1404270B1 - Modulatori allosterici positivi di mglur5 per l'impiego come medicamento nel trattamento terapeutico della sindrome di phelan-mcdermid - Google Patents

Modulatori allosterici positivi di mglur5 per l'impiego come medicamento nel trattamento terapeutico della sindrome di phelan-mcdermid

Info

Publication number
IT1404270B1
IT1404270B1 ITTO2011A000169A ITTO20110169A IT1404270B1 IT 1404270 B1 IT1404270 B1 IT 1404270B1 IT TO2011A000169 A ITTO2011A000169 A IT TO2011A000169A IT TO20110169 A ITTO20110169 A IT TO20110169A IT 1404270 B1 IT1404270 B1 IT 1404270B1
Authority
IT
Italy
Prior art keywords
allglass
phelan
mglur5
modulators
medication
Prior art date
Application number
ITTO2011A000169A
Other languages
English (en)
Inventor
Elena Dvoretskova
Carlo Sala
Chiara Verpelli
Alexander Dityatev
Original Assignee
Fond Istituto Italiano Di Tecnologia
Consiglio Nazionale Ricerche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fond Istituto Italiano Di Tecnologia, Consiglio Nazionale Ricerche filed Critical Fond Istituto Italiano Di Tecnologia
Priority to ITTO2011A000169A priority Critical patent/IT1404270B1/it
Priority to PCT/IB2012/050894 priority patent/WO2012117334A1/en
Publication of ITTO20110169A1 publication Critical patent/ITTO20110169A1/it
Application granted granted Critical
Publication of IT1404270B1 publication Critical patent/IT1404270B1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ITTO2011A000169A 2011-02-28 2011-02-28 Modulatori allosterici positivi di mglur5 per l'impiego come medicamento nel trattamento terapeutico della sindrome di phelan-mcdermid IT1404270B1 (it)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ITTO2011A000169A IT1404270B1 (it) 2011-02-28 2011-02-28 Modulatori allosterici positivi di mglur5 per l'impiego come medicamento nel trattamento terapeutico della sindrome di phelan-mcdermid
PCT/IB2012/050894 WO2012117334A1 (en) 2011-02-28 2012-02-27 Mglur5 positive allosteric modulators for use in the treatment phelan-mcdermid syndrome

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITTO2011A000169A IT1404270B1 (it) 2011-02-28 2011-02-28 Modulatori allosterici positivi di mglur5 per l'impiego come medicamento nel trattamento terapeutico della sindrome di phelan-mcdermid

Publications (2)

Publication Number Publication Date
ITTO20110169A1 ITTO20110169A1 (it) 2012-08-29
IT1404270B1 true IT1404270B1 (it) 2013-11-15

Family

ID=43976498

Family Applications (1)

Application Number Title Priority Date Filing Date
ITTO2011A000169A IT1404270B1 (it) 2011-02-28 2011-02-28 Modulatori allosterici positivi di mglur5 per l'impiego come medicamento nel trattamento terapeutico della sindrome di phelan-mcdermid

Country Status (2)

Country Link
IT (1) IT1404270B1 (it)
WO (1) WO2012117334A1 (it)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014210538A1 (en) * 2013-06-28 2014-12-31 The Regents Of The University Of California Treating cognitive deficits associated with noonan syndrome
CA3084457A1 (en) * 2017-10-27 2019-05-02 Amo Pharma Ltd. Methods of treating phelan mcdermid syndrome using farnesyl dibenzodiazepinones
CN113222975B (zh) * 2021-05-31 2023-04-07 湖北工业大学 一种基于改进U-net的高精度视网膜血管分割方法

Also Published As

Publication number Publication date
ITTO20110169A1 (it) 2012-08-29
WO2012117334A8 (en) 2013-05-10
WO2012117334A1 (en) 2012-09-07

Similar Documents

Publication Publication Date Title
IL285843A (en) Ibrutinib for use in the treatment of chronic graft versus host disease
IL234023A0 (en) New compositions for treating amyotrophic lateral sclerosis
HRP20181378T1 (hr) Postupci liječenja pedijatrijskih pacijenata deksmedetomidinom
HUE039864T2 (hu) Gyógyászati készítmények CFTR-közvetítette betegségek kezelésére
IL231533B (en) Fusion proteins for treating metabolic disorders
PL2717692T3 (pl) Kwasy tetrahydrokannabinol-11-owe do stosowania w leczeniu chorób zwłóknieniowych
IL235512B (en) Phenylbenzamide derivatives for use in treating diseases mediated by aquaporin
IL229474B (en) Cannabinoids for use in the treatment of neuropathic pain
PL2582366T3 (pl) Kombinacja farmaceutyczna do leczenia bólu
HUE053565T2 (hu) Adagolási rendek Pompe betegség kezelésére
HUE054196T2 (hu) Terápiás szerek nemkívánatos sejtproliferációhoz kapcsolódó betegségek kezelésére
IL233313A0 (en) Composition of novel carbohydrate drug for treatment of human diseases
IL228030B (en) Compounds for treating hyperuricemia and metabolic disorders associated with hyperuricemia
IL229858B (en) Polypeptides and uses thereof for tratment of autoimmune disorders and infection
PL2613798T5 (pl) Zastosowanie lizosomalnej kwaśnej lipazy do leczenia niedoboru lizosomalnej kwaśnej lipazy u pacjentów
EP2850093A4 (en) THERAPEUTIC IL-13 POLYPEPTIDES
GB201511770D0 (en) Novel pharmaceutical formulationsand their use in the treatment of periodontal disease
IL234606B (en) Novel methods and composition for treatment of disease
IL227747A0 (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
EP2522360A4 (en) VACCINE FOR TAUTOPATHY TREATMENT
LT2872145T (lt) Sujungti benzazepinai tureto sindromui gydyti
ITRM20120530A1 (it) Compounds for use in the treatment of parasitic diseases
PL2904009T3 (pl) Związki do leczenia blokady mielinizacji w chorobach związanych z ekspresją białka otoczki herv-w
EP2861243A4 (en) INTRANASAL ADMINISTRATION OF CELL PERMEABLES THERAPEUTICS FOR THE TREATMENT OF Oedemas
IT1404270B1 (it) Modulatori allosterici positivi di mglur5 per l'impiego come medicamento nel trattamento terapeutico della sindrome di phelan-mcdermid